Source: Resumos. Conference titles: International conference on tumor microenvironment. Unidade: FM
Subjects: ANTINEOPLÁSICOS, MELANOMA, INIBIDORES DE CRESCIMENTO, INIBIDORES QUÍMICOS
ABNT
ANDRADE, L. N. S. et al. The BKB1 receptor antagonist R715 increases melanoma vascular permeability leading to improved sensitivity to the chemotherapeutic agent dacarbazine. 2007, Anais.. Bologna, Italia: Faculdade de Medicina, Universidade de São Paulo, 2007. . Acesso em: 28 abr. 2024.APA
Andrade, L. N. S., Pinheiro, M. C., Nonogaki, S., Nantel, F., Battistini, B., Sirois, P., & Chammas, R. (2007). The BKB1 receptor antagonist R715 increases melanoma vascular permeability leading to improved sensitivity to the chemotherapeutic agent dacarbazine. In Resumos. Bologna, Italia: Faculdade de Medicina, Universidade de São Paulo.NLM
Andrade LNS, Pinheiro MC, Nonogaki S, Nantel F, Battistini B, Sirois P, Chammas R. The BKB1 receptor antagonist R715 increases melanoma vascular permeability leading to improved sensitivity to the chemotherapeutic agent dacarbazine. Resumos. 2007 ;[citado 2024 abr. 28 ]Vancouver
Andrade LNS, Pinheiro MC, Nonogaki S, Nantel F, Battistini B, Sirois P, Chammas R. The BKB1 receptor antagonist R715 increases melanoma vascular permeability leading to improved sensitivity to the chemotherapeutic agent dacarbazine. Resumos. 2007 ;[citado 2024 abr. 28 ]